March 10, 2013Open Access

Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non–ST-Segment Elevation Myocardial Infarction

Structured PICO

Does inclacumab reduce myocardial damage after PCI in patients with non-ST-segment elevation myocardial infarction?

Population

Patients with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI)

Intervention

Inclacumab (P-selectin antagonist)

Outcome

Myocardial damage after PCIsurrogate

Inclacumab may reduce myocardial damage following percutaneous coronary intervention in patients with NSTEMI.

Abstract

Inclacumab appears to reduce myocardial damage after PCI in patients with non-ST-segment elevation myocardial infarction. (A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction Non-STEMI Undergoing Percutaneous Coronary Intervention; NCT01327183).

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Tardif et al. (Sun,) studied this question.

synapsesocial.com/papers/69d5708475589c71d767dcd2 https://doi.org/https://doi.org/10.1016/j.jacc.2013.03.003

AI에게 질문

Bookmark

View Full Paper